Short-Term Outcomes of Bimatoprost Sustained-Release Intracameral Implant in Glaucoma.
Journal
Journal of glaucoma
ISSN: 1536-481X
Titre abrégé: J Glaucoma
Pays: United States
ID NLM: 9300903
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
received:
25
03
2023
accepted:
08
07
2023
medline:
31
8
2023
pubmed:
31
7
2023
entrez:
31
7
2023
Statut:
ppublish
Résumé
This retrospective study found a statistically significant reduction in mean intraocular pressure (IOP) and the number of medications after intracameral Bimatoprost sustained release (SR) injection in patients with glaucoma. A history of selective laser trabeculoplasty (SLT) did not impact treatment outcomes. To determine outcomes of Bimatoprost SR on IOP and the number of topical IOP-lowering medications in patients with glaucoma. A secondary objective was to determine the outcomes of Bimatoprost SR in patients with a prior history of SLT. Retrospective case series. One hundred eighteen eyes from 84 patients that received Bimatoprost SR by 6 glaucoma specialists at Wills Eye Hospital from March 2020 to September 2021 were examined. The intervention was a single injection of intracameral Bimatoprost SR. The main outcome measures included IOP and the number of medications. The most recent mean follow-up time for all eyes was 27.8 ± 18.6 weeks. The mean posttreatment IOP at the most recent follow-up of 16.6 ± 5.3 mm Hg was significantly lower than the mean under-therapy pretreatment IOP of 18.5 ± 5.7 mm Hg for all eyes ( P < 0.01). The mean posttreatment number of medications at the most recent follow-up of 1.3 ± 1.3 decreased compared with the number of pretreatment medications of 2.1 ± 1.4 for all eyes ( P < 0.01). Analysis of multilevel models controlling for demographic variables demonstrated a statistically significant reduction in IOP and number of medications posttreatment ( P < 0.01). A prior history of SLT (n = 54) had no impact on treatment for both IOP and the number of medications ( P > 0.1 for both). Intracameral Bimatoprost SR reduced IOP and decreased the number of medications. Prior history of SLT did not impact Bimatoprost SR treatment outcomes.
Identifiants
pubmed: 37523637
doi: 10.1097/IJG.0000000000002271
pii: 00061198-990000000-00248
doi:
Substances chimiques
Bimatoprost
QXS94885MZ
Delayed-Action Preparations
0
Antihypertensive Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
738-743Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure: R.M.N.: Allergan/Abbvie. M.R.M.: Allergan, Glaukos, Bausch and Lomb, Alcon, Nicox, Santen, Qura. M.J.P.: New World Medical. N.N.K.: Abbvie/Allergan, Guardion Health Services Inc, Equinox, Nicox, Olleyes, Santen, Glaukos, Diopsys, Aerie, Regeneron, Alimera, Genetech. D.L.: Allergan, Glaukos, New World Medical, Ocular Therapeutix, Olleyes, Equinox, Mati, Nicox, Santen. The remaining authors declare no conflict of interest.
Références
Resnikoff S, Pascolini D, Etya’ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82:844–851.
Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. Br J Ophthalmol. 2012;96:614–618.
Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262–267.
GBD 2019. Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9:e144–e160.
American Academy of Ophthalmology. Primary open angle glaucoma preferred practice pattern; November 2020. Accessed December 20, 2022. https://www.aao.org/preferred-practice-pattern/primary-open-angle-glaucoma-ppp
Lusthaus J, Goldberg I. Current management of glaucoma. Med J Aust. 2019;210:180–187.
Gatwood J, Brooks C, Meacham R, et al. Facilitators and barriers to glaucoma medication adherence. J Glaucoma. 2022;31:31–36.
Newman-Casey PA, Robin AL, Blachley T, et al. The most common barriers to glaucoma medication adherence: a cross-sectional survey. Ophthalmology. 2015;122:1308–1316.
Craven ER, Walters T, Christie WC, et al. 24-month phase I/II clinical trial of bimatoprost sustained-release implant (Bimatoprost SR) in glaucoma patients. Drugs. 2020;80:167–179.
Bacharach J, Tatham A, Ferguson G, et al. Phase 3, randomized, 20-month study of the efficacy and safety of Bimatoprost implant in patients with open-angle glaucoma and ocular hypertension (ARTEMIS 2). Drugs. 2021;81:2017–2033.
Medeiros FA, Walters TR, Kolko M, et al. Phase 3, randomized, 20-month study of Bimatoprost implant in open-angle glaucoma and ocular hypertension (ARTEMIS 1). Ophthalmology. 2020;127:1627–1641.
Medeiros FA, Sheybani A, Shah MM, et al. Single administration of intracameral Bimatoprost implant 10 µg in patients with open-angle glaucoma or ocular hypertension. Ophthalmol Ther. 2022;11:1517–1537.
Stubeda H, Quach J, Gao J, et al. Comparing five criteria for evaluating glaucomatous visual fields. Am J Ophthalmol. 2022;237:154–163.
Lai Y, Wu Y, Chai C, et al. The effect of patient education and telemedicine reminders on adherence to eye drops for glaucoma. Ophthalmol Glaucoma. 2020;3:369–376.
Shu YH, Wu J, Luong T, et al. Topical medication adherence and visual field progression in open-angle glaucoma: analysis of a large US Health Care System. J Glaucoma. 2021;30:1047–1055.
Kim CY, Park KH, Ahn J, et al. Treatment patterns and medication adherence of patients with glaucoma in South Korea. Br J Ophthalmol. 2017;101:801–807.
Movahedinejad T, Adib-Hajbaghery M. Adherence to treatment in patients with open-angle glaucoma and its related factors. Electron Physician. 2016;8:2954–2961.
Djafari F, Lesk MR, Harasymowycz PJ, et al. Determinants of adherence to glaucoma medical therapy in a long-term patient population. J Glaucoma. 2009;18:238–243.
Servat JJ, Bernardino CR. Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue. Drugs Aging. 2011;28:267–282.
Ishibashi T, Yokoi N, Kinoshita S. Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. J Glaucoma. 2003;12:486–490.
Baudouin C, Pisella PJ, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology. 1999;106:556–563.
Baudouin C. Side effects of antiglaucomatous drugs on the ocular surface. Curr Opin Ophthalmol. 1996;7:80–86.
Noecker R, Miller KV. Benzalkonium chloride in glaucoma medications. Ocul Surf. 2011;9:159–162.
Sarkar J, Chaudhary S, Namavari A, et al. Corneal neurotoxicity due to topical benzalkonium chloride. Invest Ophthalmol Vis Sci. 2012;53:1792–1802.
Ivakhnitskaia E, Souboch V, Dallacasagrande V, et al. Benzalkonium chloride, a common ophthalmic preservative, compromises rat corneal cold sensitive nerve activity. Ocul Surf. 2022;26:88–96.
Ghosn C, Rajagopalan L, Ugarte S, et al. Intraocular pressure-lowering efficacy of a sustained-release Bimatoprost implant in dog eyes pretreated with selective laser trabeculoplasty. J Ocul Pharmacol Ther. 2022;38:311–318.